ACRSAclaris Therapeutics, Inc.
$3.78+105% 1Y
$3.78
$1.8152 weeks$6.54
The financials
Aclaris Therapeutics, Inc. by the numbers
Aclaris Therapeutics, Inc. (ACRS) reported revenue of $1.6M in Q2 2026 (quarter ended Jun 30, 2026), down 8.3% from the same quarter a year earlier. That came with a gross margin of 87% and net loss of $22M. For the full year FY2025, revenue was $7.8M (−58% year on year) and net income −$65M. Its largest product in Q2 2026 was Dermatology Therapeutics at $1.3M, 78% of the disclosed total, well ahead of Contract Research at 22%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.6M | $1.8M | −8.3% |
| Gross profit | $1.4M | $1.3M | +12% |
| Operating income | −$24M | −$18M | n/a |
| Net income | −$22M | −$15M | n/a |
| Diluted EPS | −$0.15 | −$0.13 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Dermatology Therapeutics | $1.3M | 78% |
| Contract Research | $356K | 22% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.6M (-18%)
Dermatology Therapeutics grew -4.6% year on yearContract Research -19% year on year
Segment Latestquarter on quarteryear on year
- Dermatology Therapeutics$1.3M$1.3Mquarter on quarter -13%year on year -4.6%-13%-4.6%
- Contract Research$356.0K$356.0Kquarter on quarter -34%year on year -19%-34%-19%